{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T01:44:18Z","timestamp":1771033458444,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Research and Development Fund","award":["26-A-26"],"award-info":[{"award-number":["26-A-26"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12185-023-03561-7","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T16:48:07Z","timestamp":1677170887000},"page":"292-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"118","author":[{"given":"Kayoko","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhi","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Hosoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"20","key":"3561_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"12","key":"3561_CR2","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402\u20138. https:\/\/doi.org\/10.1182\/blood-2010-09-310342.","journal-title":"Blood"},{"issue":"5","key":"3561_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ajh.23144","volume":"87","author":"JO Armitage","year":"2012","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(5):511\u20139. https:\/\/doi.org\/10.1002\/ajh.23144.","journal-title":"Am J Hematol"},{"issue":"4","key":"3561_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","volume":"19","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4):602\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.006.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"3561_CR5","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4(19):4640\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2020002396.","journal-title":"Blood Adv"},{"issue":"8","key":"3561_CR6","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3109\/10428194.2016.1160082","volume":"57","author":"A Petrich","year":"2016","unstructured":"Petrich A, Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma. 2016;57(8):1755\u201365. https:\/\/doi.org\/10.3109\/10428194.2016.1160082.","journal-title":"Leuk Lymphoma"},{"key":"3561_CR7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and hdac inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016. https:\/\/doi.org\/10.1101\/cshperspect.a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"3561_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","volume":"19","author":"Y Ito","year":"2019","unstructured":"Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19(3):197\u2013209. https:\/\/doi.org\/10.1080\/14712598.2019.1572746.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"3561_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.37.4223.","journal-title":"J Clin Oncol"},{"key":"3561_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bcj.2015.83","volume":"5","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5:357.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3561_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","volume":"13","author":"AC Mamez","year":"2020","unstructured":"Mamez AC, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56. https:\/\/doi.org\/10.1186\/s13045-020-00892-4.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"3561_CR12","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370. https:\/\/doi.org\/10.1182\/blood.2020009004.","journal-title":"Blood"},{"key":"3561_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15427","author":"S Fukuhara","year":"2022","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022. https:\/\/doi.org\/10.1111\/cas.15427.","journal-title":"Cancer Sci"},{"issue":"1","key":"3561_CR14","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1038\/s41467-019-12032-9","volume":"10","author":"Z Li","year":"2019","unstructured":"Li Z, Zhang X, Xue W, Zhang Y, Li C, Song Y, et al. Recurrent GNAQ mutation encoding T96S in natural killer\/T cell lymphoma. Nat Commun. 2019;10(1):4209. https:\/\/doi.org\/10.1038\/s41467-019-12032-9.","journal-title":"Nat Commun"},{"issue":"9","key":"3561_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/icb.2014.53","volume":"92","author":"D Wang","year":"2014","unstructured":"Wang D, Zhang Y, He Y, Li Y, Lund FE, Shi G. The deficiency of Galphaq leads to enhanced T-cell survival. Immunol Cell Biol. 2014;92(9):781\u201390. https:\/\/doi.org\/10.1038\/icb.2014.53.","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"3561_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1084\/jem.20092735","volume":"207","author":"RS Misra","year":"2010","unstructured":"Misra RS, Shi G, Moreno-Garcia ME, Thankappan A, Tighe M, Mousseau B, et al. G alpha q-containing G proteins regulate B cell selection and survival and are required to prevent B cell-dependent autoimmunity. J Exp Med. 2010;207(8):1775\u201389. https:\/\/doi.org\/10.1084\/jem.20092735.","journal-title":"J Exp Med"},{"issue":"5","key":"3561_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41379-019-0415-5","volume":"33","author":"IA Montes-Mojarro","year":"2020","unstructured":"Montes-Mojarro IA, Chen BJ, Ramirez-Ibarguen AF, Quezada-Fiallos CM, Perez-Baez WB, Duenas D, et al. Mutational profile and EBV strains of extranodal NK\/T-cell lymphoma, nasal type in Latin America. Mod Pathol. 2020;33(5):781\u201391. https:\/\/doi.org\/10.1038\/s41379-019-0415-5.","journal-title":"Mod Pathol"},{"issue":"3","key":"3561_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/bmt.2015.280","volume":"51","author":"AC Mamez","year":"2016","unstructured":"Mamez AC, Levy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, et al. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2016;51(3):358\u201364. https:\/\/doi.org\/10.1038\/bmt.2015.280.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3561_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","volume":"64","author":"KM VanderMolen","year":"2011","unstructured":"VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64(8):525\u201331. https:\/\/doi.org\/10.1038\/ja.2011.35.","journal-title":"J Antibiot (Tokyo)"},{"issue":"9","key":"3561_CR20","doi-asserted-by":"publisher","first-page":"1341031","DOI":"10.1080\/2162402X.2017.1341031","volume":"6","author":"Y Chu","year":"2017","unstructured":"Chu Y, Yahr A, Huang B, Ayello J, Barth M. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology. 2017;6(9):1341031.","journal-title":"Oncoimmunology."},{"key":"3561_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2021-152833","volume":"138","author":"ZB Chitra Hosing","year":"2021","unstructured":"Chitra Hosing ZB, Ali AM, Valdez BC, Andersson BS, Popat UR, Vasu S, Larkin K, Penza S, Choe H, Saad A, de Lima MJG, Wei L, McLaughlin E, Nakkula R, Campbell A, Trikha P, Puto M, William BM, Champlin RE, Lee DA, Brammer JE. Romidepsin in conditioning and maintenance mitigates relapse risk and enhances nk-cell cytotoxicity in patients receiving allogeneic stem cell transplant for aggressive t-cell malignancies: results of a phase i\/ii clinical trial. Blood. 2021;138:553.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03561-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:55:30Z","timestamp":1689864930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03561-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3561"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03561-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KT has received honorarium from Sysmex. YI has received honorarium from Novartis, Janssen, Meiji Seika Pharma, and Kyowa Kirin. SM has received honorarium from Celgene\/Bristol Myers Squibb, Chugai, CSL Behring, Daiichi-Sankyo, Eisai, Novartis, SymBio, and Takeda, and has a consulting or advisory role of Takeda, Celgene\/BMS, Daiichi-Sankyo, Novartis, Celgene\/Bristol Myers Squib, Gilead Sciences, and Genmab. SF has received honorarium from Janssen, Takeda, Zenyaku, Otsuka, Astrazeneca, Abbvie, Ono, and Chugai, and a research fund from Chugai and Loxo Oncology. KK has received a research fund from Otsuka Pharmaceutical and honorarium from Otsuka Pharmaceutical and Bristol Myers Squibb. KI has received honorarium from Eisai, Chugai, Janssen, AstraZeneca, Novartis, Bristol Myers Squibb, Celgene, Kyowa Kirin, Abbvie, Ono Pharmaceutical, Eli Lilly, MSD, Daiichi Sankyo, Kyorin Pharmaceutical, Symbio, Takeda, Allergan Japan, and FIJIFILM Toyama Chemical, and a research grant from Celgene\/Bristol Myers Squibb, MSD, AstraZeneca, AbbVie, Eisai, Incyte, Solasia Pharma, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Ono Pharmaceutical, Daiichi Sankyo, Chugai, Takeda, Beigene, Genmab, Otsuka, and LOXO Oncology, and has a consulting or advisory role of Kyowa Kirin, Eisai, Genmab, AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Takeda, Celgene, and AstraZeneca. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}